Adjuvant and neoadjuvant imatinib therap
โ
Burton L. Eisenberg; Jonathan C. Trent
๐
Article
๐
2011
๐
John Wiley and Sons
๐
French
โ 212 KB
## Abstract Although surgery remains the mainstay for the treatment of primary gastrointestinal stromal tumors (GIST), a significant number of patients experience disease recurrence within 5 years of surgery. The emergence of imatinib therapy for the treatment of patients with advanced GIST has off